Log in

Relevant bibliographies by topics / An anticholinergic ipratropium bromidum / Journal articles

To see the other types of publications on this topic, follow the link: An anticholinergic ipratropium bromidum.

Journal articles on the topic 'An anticholinergic ipratropium bromidum'

Author: Grafiati

Published: 7 June 2025

Last updated: 2 August 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'An anticholinergic ipratropium bromidum.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Mustafa, Lirim, Hilmi Islami, Mirlinda Havolli, et al. "Effect of Cholinergic Receptor Antagonists on the Potentiation of the Effect of Adenosine Receptor Blockers in People with Bronchial Asthma." Biomedical and Pharmacology Journal 17, no. 2 (2024): 1069–77. http://dx.doi.org/10.13005/bpj/2923.

Full text

Abstract:

Background: The interaction between adenosine receptor blockers and anticholinergic substances in the treatment of bronchial asthma is an area of interest. The efficacy of such combinations in managing bronchial asthma and bronchial hypersensitivity needs to be explored further. Understanding lung function parameters such as airway resistance and intrathoracic gas volume is crucial for evaluating the effects of these medications. Objective: This study aimed to investigate the effect of combining the adenosine receptor blocker, bamifylline, with the anticholinergic substance, ipratropium bromid

APA, Harvard, Vancouver, ISO, and other styles

2

George, Shone, Shiby Sara Shaji, Manish Mohan, M. M. Shahul Hameed, and Jacob Jesurun. "Case report on Ipratropium Bromide induced Anisocoria." Indian Journal of Pharmacy and Pharmacology 10, no. 4 (2024): 323–25. http://dx.doi.org/10.18231/j.ijpp.2023.054.

Full text

Abstract:

Anisocoria or unequal pupil size is an alarming sign of a neurologic emergency, especially when the patient is in a critical care setting. It is important to identify the aetiology of anisocoria and consider drug-induced anisocoria as a possible aetiology after ruling out underlying pathology if any. Ipratropium bromide, an anticholinergic drug, can cause anisocoria. This case report emphasises Ipratropium bromide-induced anisocoria.

APA, Harvard, Vancouver, ISO, and other styles

3

Pant, P., B. Yadav, R. Koju, et al. "Role of tiotropium in chronic obstructive pulmonary disease exacerbation." Journal of Institute of Medicine Nepal 32, no. 2 (2010): 5–10. http://dx.doi.org/10.59779/jiomnepal.496.

Full text

Abstract:

Introduction: Chronic obstructive pulmonary disease (COPD) remains a major public health problem. Many patients suffering from chronic obstructive lungs diseases are of poor economic status, mostly illiterate, therefore has a direct bearing on patient compliance. Tiotropium is a new anticholinergic therapy for chronic obstructive pulmonary disease that differs from ipratropium by its functional relative selectively for musarinic receptor subtypes and which allows single dosing a day. This study presents a cost-effectiveness, efficacy, and side-effects of Ipratropium bromide and Tiotropium in C

APA, Harvard, Vancouver, ISO, and other styles

4

Somand, Heather, and Tami L. Remington. "Tiotropium: A Bronchodilator for Chronic Obstructive Pulmonary Disease." Annals of Pharmacotherapy 39, no. 9 (2005): 1467–75. http://dx.doi.org/10.1345/aph.1e469.

Full text

Abstract:

OBJECTIVE: To review the scientific literature evaluating the efficacy and tolerability of tiotropium bromide, a new bronchodilator indicated for treatment of chronic obstructive pulmonary disease (COPD). DATA SOURCES: Articles were identified through searches of MEDLINE (1966–January 2005) using the key words tiotropium, BA 679 BR, chronic obstructive pulmonary disease, and anticholinergic agents. Additional citations were identified from bibliographies of publications cited. STUDY SELECTION AND DATA EXTRACTION: Experimental and observational studies of tiotropium bromide were selected. Trial

APA, Harvard, Vancouver, ISO, and other styles

5

Mutmainnah, Safina, Yusup Subagio Sutanto, Jatu Aphridasari, and A. Farih Raharjo. "The Effect of Inhaled Ipratropium Bromide as a Premedication For Bronchoscopy on Dyspnea, Cough, and Tracheobronchial Secretion." Jurnal Respirologi Indonesia 43, no. 4 (2023): 255–61. http://dx.doi.org/10.36497/jri.v43i4.256.

Full text

Abstract:

Background: Bronchoscopy is a minimally invasive procedure used for diagnostic examination and intervention of the airways. Patient comfort and cooperation during bronchoscopy are very important because they affect the success and outcome. The sympathetic anticholinergic effect of ipratropium bromide can improve procedure tolerance and airway visualization. This study was conducted to analyze the effect of inhaled ipratropium bromide as a bronchoscopy premedication for the assessment of dyspnea, cough, and tracheobronchial secretion.Methods: This was a clinical study with a quasi-experimental

APA, Harvard, Vancouver, ISO, and other styles

6

Jennings, S. J., J. B. Warren, and N. B. Pride. "Airway caliber and the work of breathing in humans." Journal of Applied Physiology 63, no. 1 (1987): 20–24. http://dx.doi.org/10.1152/jappl.1987.63.1.20.

Full text

Abstract:

Mechanical work rate of breathing was measured in five normal subjects during voluntary eucapnic hyperventilation at rates of approximately 10, 20, 40, 60, and 80 l/min before and after inhalation of 1 mg of ipratropium bromide, an anticholinergic agent. Chest wall recoil pressure was measured over a range of lung volumes in each subject and was used as the reference pressure in the calculation of work rate. There was little change in elastic or resistive work rate at rest when vagal tone was reduced by ipratropium. The mean work at 40, 60, and 80 l/min was 8.9, 17.2, and 34.0 cmH2O.l–1.s befo

APA, Harvard, Vancouver, ISO, and other styles

7

Punin, D. A. "Effect of the combination of a short-acting β2-agonist plus an anticholinergic drug on the efficacy of coronary blood flow measured by applanation tonometry in chronic obstructive pulmonary disease". Russian Medical Inquiry 4, № 4 (2020): 199–206. http://dx.doi.org/10.32364/2587-6821-2020-4-4-199-206.

Full text

Abstract:

Background: bronchodilators are the major class of drugs prescribed for chronic obstructive pulmonary disease (COPD). Meanwhile, treatment strategies for obstructive lung disease using bronchodilators are continually discussed and reviewed, in particular, with regard to their potential effect on cardiovascular system. Aim: to evaluate the effect of the combination of a short-acting β2-agonist plus an anticholinergic medication (fenoterol 50 μg/dose + ipratropium bromide 20 μg/dose, 2 doses) on the efficacy of coronary blood flow in COPD patients. Patients and Methods: spirometry with bronchodi

APA, Harvard, Vancouver, ISO, and other styles

8

Kosirog-Glowacki, Jane L., and Linda R. Bressler. "Cyclophosphamide-Induced Facial Discomfort." Annals of Pharmacotherapy 28, no. 2 (1994): 197–99. http://dx.doi.org/10.1177/106002809402800208.

Full text

Abstract:

OBJECTIVE: To report the occurrence of cyclophosphamide-induced facial discomfort in patients at our institution, to review previous literature reports, and to discuss possible methods of prevention. SETTING: An oncology clinic in a university teaching hospital. PATIENTS: From January 1990 to March 1993, 14 patients experienced uncomfortable sensations of the skin or mucous membranes associated with cyclophosphamide administration. Details pertaining to each patient are described. INTERVENTIONS: Initial interventions included changing the duration of infusion or concentration of cyclophosphami

APA, Harvard, Vancouver, ISO, and other styles

9

Lloberes, P., L. Ramis, JM Montserrat, et al. "Effect of three different bronchodilators during an exacerbation of chronic obstructive pulmonary disease." European Respiratory Journal 1, no. 6 (1988): 536–39. http://dx.doi.org/10.1183/09031936.93.01060536.

Full text

Abstract:

This study evaluates the effect of three different bronchodilators (beta 2-adrenergic, anticholinergic and methylxanthine) alone and in randomized sequence, during an exacerbation in thirteen patients with chronic obstructive pulmonary disease. Dose-response curves were obtained for inhaled salbutamol and inhaled ipratropium bromide. The bronchodilator effect of a perfusion of aminophylline was also assessed. When a plateau of bronchodilatation was achieved with one agent, one dose of a second bronchodilator was administered to see whether additional bronchodilation could be achieved. The incr

APA, Harvard, Vancouver, ISO, and other styles

10

SAITO, Hitoshi, Toshihito TSUBOKAWA, and Takehisa SAITO. "Effect of an anticholinergic agent, ipratropium bromide, on nasal ciliary epithelium." Practica Oto-Rhino-Laryngologica 79, no. 1 (1986): 151–59. http://dx.doi.org/10.5631/jibirin.79.151.

Full text

APA, Harvard, Vancouver, ISO, and other styles

11

Pitkäranta, Anne, Margaret T. Wecker, David C. Korts, and Frederick G. Hayden. "Combined Intranasal Ipratropium Bromide and Oxymetazoline in Experimental Rhinovirus Infection." American Journal of Rhinology 12, no. 2 (1998): 125–30. http://dx.doi.org/10.2500/105065898781390316.

Full text

Abstract:

The topical anticholinergic ipratropium bromide and topical decongestant oxymetazoline were tested to determine whether oxymetazoline alone and the combination were well tolerated and reduced rhinorrhea and middle ear pressure abnormalities during experimental rhinovirus infection. The study was double-blind, placebo-controlled, and double dummy in design. Healthy volunteers (n = 109) with low serum neutralizing antibody titer (≤1:2) were. Treatments inoculated with rhinovirus (type 39 or Hank's strain) and randomized to treatment with ipra-tropium bromide 0.06% two sprays per nostril (84 μg p

APA, Harvard, Vancouver, ISO, and other styles

12

Raja, Naima Fazil, Asmat Perveen, Imran Mahmood Khan, Maqbool Hussain, Jai Krishin, and Sajid Hussain Sherazi. "Comparison of Combined Nebulization of Salbutamol-Ipratropium Bromide with Salbutamol Alone in Children with Mild and Moderate Acute Asthma." Journal of Rawalpindi Medical College 24, no. 3 (2020): 208–13. http://dx.doi.org/10.37939/jrmc.v24i3.1213.

Full text

Abstract:

ntroduction: The β2 agonists are potent bronchodilators but their repeated and high doses are related to adrenergic side effects. While ipratropium bromide, an anticholinergic bronchodilator has less adverse effects. Objective: To compare the efficacy of combined nebulization of salbutamol-ipratropium bromide with salbutamol alone in children with mild and moderate acute asthma. Materials and Methods: This randomised control trial was done on 80 children aged 5 to 12 years who presented with mild to moderate acute asthma in the emergency department of Children Hospital of Pakistan

APA, Harvard, Vancouver, ISO, and other styles

13

Larsson, K., S. Bevegard, and B. Mossberg. "Posture-induced airflow limitation in asthma: relationship to plasma catecholamines and an inhaled anticholinergic agent." European Respiratory Journal 1, no. 5 (1988): 458–63. http://dx.doi.org/10.1183/09031936.93.01050458.

Full text

Abstract:

Postural influence on ventilatory function was investigated in thirteen asthmatic subjects on three consecutive days starting at 10.00 am. Lung function was measured in the seated position before and after four hours lying supine. Peak expiratory flow (PEF) was measured every 0.5 h in the supine position. Blood samples for determination of plasma catecholamines were collected before, during and after lying supine. After the initial lung function testing, placebo or ipratropium bromide (0.125 mg) was inhaled. On the third day the whole trial was performed seated, without any drug, as a control

APA, Harvard, Vancouver, ISO, and other styles

14

Stojkovic-Andjelkovic, Andjelka, Slobodan Obradovic, Biljana Vuletic, and Vladimir Radlovic. "Position of anticholinergic drugs in the treatment of childhood asthma." Srpski arhiv za celokupno lekarstvo 138, no. 5-6 (2010): 379–86. http://dx.doi.org/10.2298/sarh1006379s.

Full text

Abstract:

Anticholinergic drugs block muscarinic effect of acetylcholine on the receptors of postjunctional membranes and so inhibit the answer of the postganglionic parasympathetic nerve. The loss of M2 muscarinic receptors function occurs in asthmatics and it contributes to bronchial hyperresponsiveness and it is not a chronic feature of asthma, instead it characterizes asthma exacerbation. The loss of M2 muscarinic receptor function in children and adults happens during antigen bronchoprovocation or during exposition of asthmatics to ozone. After inhalation, ipratropium bromide (IB) can be found in a

APA, Harvard, Vancouver, ISO, and other styles

15

Cowan, Ian. "Comparison of the anticholinergic bronchodilator ipratropium bromide with metaproterenol in chronic obstructive pulmonary disease." Annals of Emergency Medicine 16, no. 3 (1987): 366–67. http://dx.doi.org/10.1016/s0196-0644(87)80195-6.

Full text

APA, Harvard, Vancouver, ISO, and other styles

16

Zaniolo, Orietta, Viola Sacchi, and Roberto W. Dal Negro. "Tiotropium in COPD: clinical outcomes and economic evidence." Farmeconomia. Health economics and therapeutic pathways 11, no. 1 (2010): 27–41. http://dx.doi.org/10.7175/fe.v11i1.178.

Full text

Abstract:

Tiotropium bromide is a once-daily anticholinergic bronchodilator with duration of action of at least 24 hours. In clinical trials, tiotropium has been compared with placebo, ipratropium or salmeterol, the most frequently used long-acting β2 agonist. When compared with ipratropium or placebo in COPD management, tiotropium resulted associated with FEV1, dyspnoea and health-related quality of life (QoL) improvement, along with reduced exacerbation and hospitalisation rates. In comparison to salmeterol, it proved to be superior in terms of lung function improvement and exacerbation risk reduction

APA, Harvard, Vancouver, ISO, and other styles

17

Maksimov, M. L., R. A. Bontsevich, and A. A. Shikaleva. "Treatment of exacerbations of chronic obstructive pulmonary disease." Terapevt (General Physician), no. 12 (December 20, 2024): 46–55. https://doi.org/10.33920/med-12-2412-06.

Full text

Abstract:

the article contains current information on the main groups of drugs and algorithms for their use in the treatment of chronic obstructive pulmonary disease (COPD). The authors of the article show that the use of bronchodilators is a key link in the treatment of exacerbations. The effectiveness of β2‑agonists and ipratropium bromide in exacerbations of COPD is approximately the same, the advantage of β2‑agonists is a faster onset of action, and anticholinergic drugs are high safety and good tolerability. For the optimal choice of an approach to the treatment of COPD exacerbations, it is recomme

APA, Harvard, Vancouver, ISO, and other styles

18

Kaiser, Harold B., Steven R. Findlay, John W. Georgitis, et al. "The Anticholinergic Agent, Ipratropium Bromide, is Useful in the Treatment of Rhinorrhea Associated with Perennial Allergic Rhinitis." Allergy and Asthma Proceedings 19, no. 1 (1998): 23–29. http://dx.doi.org/10.2500/108854198778557962.

Full text

APA, Harvard, Vancouver, ISO, and other styles

19

Manfreda, J., NR Anthonisen, and The Lung Health Study Research Group. "The Lung Health Study." Canadian Respiratory Journal 2, no. 2 (1995): 104–11. http://dx.doi.org/10.1155/1995/694781.

Full text

Abstract:

OBJECTIVE: To determine whether smoking intervention and use of an inhaled bronchodilator can slow the rate of decline in forced expiratory volume in 1 s (FEV1) in smokers with mild obstructive pulmonary disease.DESIGN: Randomized clinical trial: participants randomized to one of three groups: smoking intervention plus inhaled bronchodilator (Atrovent; ipratropium bromide) (SIA): smoking intervention plus placebo (SIP); or no intervention (usual care, UC).SETTING: Ten centres in the United States and Canada.PARTICIPANTS: A total of 5887 smokers, aged 35 to 60 years, with FEV155 to 90% predicte

APA, Harvard, Vancouver, ISO, and other styles

20

Peters, MJ, AB Breslin, and N. Berend. "The effect of anticholinergic and beta-agonist pretreatment on bronchoconstriction induced by N-formyl-methionyl-leucyl-phenylalanine." European Respiratory Journal 2, no. 10 (1989): 946–49. http://dx.doi.org/10.1183/09031936.93.02100946.

Full text

Abstract:

N-Formyl-methionyl-leucyl-phenylalanine (FMLP), an acylated tripeptide bacterial neutrophil chemotactic factor, has been shown to be a bronchoconstrictor by inhalation in man in vivo. It thus has a putative role in the generation of bronchoconstriction associated with bacterial bronchial infection. We have investigated the effect of pretreatment with the anticholinergic agent, ipratropium bromide (IB), and the beta 2-agonist, fenoterol (F), on FMLP-induced bronchoconstriction. Ten non-asthmatic subjects aged 21-28 yrs performed dose-response curves to nebulized FMLP on 3 study days after pretr

APA, Harvard, Vancouver, ISO, and other styles

21

Tashkin, Donald P., Kumar Ashutosh, Eugene R. Bleecker, et al. "Comparison of the anticholinergic bronchodilator ipratropium bromide with metaproterenol in chronic obstructive pulmonary disease: A 90-day multi-center study." American Journal of Medicine 81, no. 5 (1986): 81–90. http://dx.doi.org/10.1016/0002-9343(86)90468-7.

Full text

APA, Harvard, Vancouver, ISO, and other styles

22

Tsvetkova, О. A., and O. O. Voronkova. "The value of the medicine fenoterol + ipratropium bromide in the treatment of exacerbations of bronchial asthma and chronic obstructive pulmonary disease." Meditsinskiy sovet = Medical Council, no. 17 (November 22, 2020): 35–39. http://dx.doi.org/10.21518/2079-701x-2020-17-35-39.

Full text

Abstract:

The purpose of the article is to determine the place of the combined bronchodilator fenoterol + ipratropium bromide in the treatment of exacerbations of bronchial asthma, COPD and recommendations on various delivery methods. The treatment of exacerbations of bronchial asthma (BA) and chronic obstructive pulmonary disease (COPD) is of interest to a general practitioner. Although this concept has lost most of its gloomy colors in the last decade thanks to the new concept of diagnosing and treating patients, the problem of providing qualified timely assistance at the time of an exacerbation remai

APA, Harvard, Vancouver, ISO, and other styles

23

Pereira Filho, Francisco de Assis, Roseli Oselka Saccardo Sarni, and Neusa Falbo Wandalsen. "Evaluation of treatment of the exacerbation of asthma and wheezing in a pediatric emergency department." Revista da Associação Médica Brasileira 66, no. 9 (2020): 1270–76. http://dx.doi.org/10.1590/1806-9282.66.9.1270.

Full text

Abstract:

SUMMARY OBJECTIVES: To evaluate the treatment of wheezing and exacerbation of asthma in a pediatric emergency unit (ED), comparing it to that recommended by the guidelines for this purpose. METHODS: Descriptive cross-sectional study through medical records survey of children and adolescents (0–15 years of age) who received medication for wheezing or asthma exacerbation from January to April 2015 in the ED. The selected treatment was compared to that recommended by the guidelines, being analyzed the variables related to the medication (number and dose of short-acting β2 agonist, associated or n

APA, Harvard, Vancouver, ISO, and other styles

24

Loureiro, Cláudia Chaves. "Influência da idade e da obstrução brônquica na resposta broncodilatadora em idosos." Acta Médica Portuguesa 24, no. 6 (2012): 905. http://dx.doi.org/10.20344/amp.1426.

Full text

Abstract:

Bronchodilator response may be influenced by airway flow limitation, age and genetics. Evidence has shown that this response increases with higher levels of airway obstruction and is altered with age and presence of specific genetic polymorphisms of the β2 adrenergic receptors.Correlate the airway flow limitation (FEV1, FVC, IC, RV) with the bronchodilation response, to β-adrenergics (salbutamol (s)) and to anticholinergics (ipratropium bromide (b)), in a group of elderly people with diagnosed asthma.We submitted a group of twelve aged individuals (>65Y), with diagnosed asthma, to a basal v

APA, Harvard, Vancouver, ISO, and other styles

25

Shao, Shu, Juan Wen, Ya Wang, and Junxiang Tang. "A clinical study on the combination of bencycloquidium bromide and montelukast in the treatment of moderate to severe allergic rhinitis." Medicine 104, no. 21 (2025): e42573. https://doi.org/10.1097/md.0000000000042573.

Full text

Abstract:

Background: Bencycloquidium bromide (BCQB) is a novel synthesized quaternary ammonium salt compound based on the classic anticholinergic drug ipratropium bromide. This study was to compare the efficacy of BCQB and montelukast (MNT) combination therapy to that of MNT monotherapy in the treatment of moderate to severe allergic rhinitis ((M/S)AR). Methods: This study enrolled enrolled 300 patients with (M/S)AR. The participants were randomized to receive BCQB (180 μg each time, qid) plus MNT (10 mg qn) (BCQB + MNT group) or MNT alone (10 mg qn) for 4 weeks. The visual analog scale (VAS) for rhino

APA, Harvard, Vancouver, ISO, and other styles

26

Maesen, FP, JJ Smeets, TJ Sledsens, FD Wald, and PJ Cornelissen. "Tiotropium bromide, a new long-acting antimuscarinic bronchodilator: a pharmacodynamic study in patients with chronic obstructive pulmonary disease (COPD). Dutch Study Group." European Respiratory Journal 8, no. 9 (1995): 1506–13. http://dx.doi.org/10.1183/09031936.95.08091506.

Full text

Abstract:

The objective of the present study was to investigate the dose-dependent bronchodilator efficacy and duration of action of the newly developed antimuscarinic agent tiotropium bromide in patients with chronic obstructive pulmonary disease (COPD). In a randomized, double-blind, placebo-controlled, crossover design, patients inhaled single doses of 10-80 micrograms tiotropium bromide and placebo, formulated in lactose powder capsules. The washout period between test doses was 72 h. Thirty five patients were enrolled in the trial (32 males and 3 females; mean age 64 yrs). Baseline forced expirator

APA, Harvard, Vancouver, ISO, and other styles

27

Pratiwi, Dyah Anggraeni Budhi, Novita Anggraini, and Nur Aeni. "Kajian DRPs dan pola peresepan pada pasien rawat inap anak dengan asma." Health Sciences and Pharmacy Journal 6, no. 1 (2022): 28–34. http://dx.doi.org/10.32504/hspj.v6i1.543.

Full text

Abstract:

The incidence of drug-related problems (DRPs) is very common occur in pediatric inpatients where treatment must be prioritized because their physiological conditions are not yet perfect so metabolism and drug absorption cannot be equated. The risk of developing DRPs results in a decrease in the patient's quality of life, increases the rate of death and disability and increases costs. Asthma is a chronic disease, the prevalence of asthma in children is high enough that it requires serious attention. In Indonesia, the prevalence of asthma in elementary school children (0-14 years) is 9.6%. This

APA, Harvard, Vancouver, ISO, and other styles

28

Easton, Paul A., Carlos Jadue, Saresh Dhingra, and Nicholas R. Anthonisen. "A Comparison of the Bronchodilating Effects of a Beta-2 Adrenergic Agent (Albuterol) and an Anticholinergic Agent (Ipratropium Bromide), Given by Aerosol Alone or in Sequence." New England Journal of Medicine 315, no. 12 (1986): 735–39. http://dx.doi.org/10.1056/nejm198609183151205.

Full text

APA, Harvard, Vancouver, ISO, and other styles

29

Mansour, E., A. Ahmed, A. Cortes, J. Caplan, R. M. Burch, and W. M. Abraham. "Mechanisms of metabisulfite-induced bronchoconstriction: evidence for bradykinin B2-receptor stimulation." Journal of Applied Physiology 72, no. 5 (1992): 1831–37. http://dx.doi.org/10.1152/jappl.1992.72.5.1831.

Full text

Abstract:

Sodium metabisulfite (MBS) is a food preservative that can trigger bronchoconstriction in asthmatic subjects. Previous studies designed to identify the mechanisms involved in this response have yielded conflicting results. We noted certain similarities between the pharmacology of MBS-induced airway responses and those elicited by bradykinin (BK), another provocating agent in asthmatic subjects. Therefore we used allergic sheep to determine whether MBS-induced bronchoconstriction 1) had a pharmacology similar to that previously seen with BK in this model, including protection by a BK B2-recepto

APA, Harvard, Vancouver, ISO, and other styles

30

Fontana, G., M. Mugnai, F. Cresci, and P. Panuccio. "Histamine-Induced Bronchial Response after Administration of Placebo, Salbutamol and a Combination of a Beta-2-Adrenergic Drug (Fenoterol) with an Anticholinergic Agent (Ipratropium Bromide) in Asymptomatic Asthma Patients." Respiration 50, no. 2 (1986): 201–5. http://dx.doi.org/10.1159/000195127.

Full text

APA, Harvard, Vancouver, ISO, and other styles

31

Steinbach, Suzanne Fields. "Anticholinergic effects of ipratropium." Journal of Pediatrics 117, no. 4 (1990): 674–75. http://dx.doi.org/10.1016/s0022-3476(05)80718-8.

Full text

APA, Harvard, Vancouver, ISO, and other styles

32

Pavlova, K. S., D. S. Mdinaradze, and O. M. Kurbacheva. "The response variability of the asthma patients to the standard pharmacotherapy." Russian Journal of Allergy 16, no. 2 (2019): 20–24. http://dx.doi.org/10.36691/rja1193.

Full text

Abstract:

Background. The aim of this study was to analyse the group of patients with asthma, who prefer to use short-acting anticholinergics (SAMA) for relief of asthma attacks. At the same time, these patients are prescribed inhaled glucocorticosteroids (ICS) in combination with long-acting P2-agonists (LABA) as a basic therapy according to the standards. Tha aim. To study the cause of low efficacy of LABA in patients with asthma who do not have a sufficient response to SABA, as well as the probability of reducing of bronchial obstruction with LAMA. Materials and methods. 12 non-smoking adults with mo

APA, Harvard, Vancouver, ISO, and other styles

33

Groeben, Harald, and Robert H. Brown. "Ipratropium Decreases Airway Size in Dogs by Preferential M2Muscarinic Receptor Blockade In Vivo." Anesthesiology 85, no. 4 (1996): 867–73. http://dx.doi.org/10.1097/00000542-199610000-00023.

Full text

Abstract:

Background Two major groups of drugs are available to prevent bronchoconstriction: beta-agonists and muscarinic blocking agents. Ipratropium is the most commonly used anticholinergic agent to treat chronic obstructive pulmonary disease. The authors studied anti-muscarinic agents to determine if they are as effective bronchodilators as beta-adrenergic agents and if not to identify the mechanism of their reduced effectiveness. Methods Six anesthetized dogs were studied using high-resolution computed tomography to measure changes in the cross-sectional area of conducting airways induced by cumula

APA, Harvard, Vancouver, ISO, and other styles

34

Chen, Jiayin, Jürgen Brockmöller, Tina Seitz, Jörg König, Mladen V. Tzvetkov, and Xijing Chen. "Tropane alkaloids as substrates and inhibitors of human organic cation transporters of the SLC22 (OCT) and the SLC47 (MATE) families." Biological Chemistry 398, no. 2 (2017): 237–49. http://dx.doi.org/10.1515/hsz-2016-0236.

Full text

Abstract:

Abstract Tropane alkaloids and their derivatives are anticholinergic drugs with narrow therapeutic range. Here we characterize the organic cation transporters from the SLC22 (OCT1, OCT2, and OCT3) and the SLC47 families (MATE1 and MATE2-K) as potential mediators of the renal and extra-renal excretion, the two major roads of elimination of these substances. All analyzed compounds inhibited and the quaternary amine derivatives ipratropium and trospium were strongly transported by OCTs and MATEs. Overexpression of OCTs or MATEs in HEK293 cells resulted in an up to 63-fold increase in the uptake o

APA, Harvard, Vancouver, ISO, and other styles

35

Cots, Josep M., Ana Moragas, Ana García-Sangenís, et al. "Effectiveness of antitussives, anticholinergics or honey versus usual care in adults with uncomplicated acute bronchitis: a study protocol of an open randomised clinical trial in primary care." BMJ Open 9, no. 5 (2019): e028159. http://dx.doi.org/10.1136/bmjopen-2018-028159.

Full text

Abstract:

IntroductionDespite the frequent use of therapies in acute bronchitis, the evidence of their benefit is lacking, since only a few clinical trials have been published, with low sample sizes, poor methodological quality and mainly in children. The objective of this study is to compare the effectiveness of three symptomatic therapies (dextromethorphan, ipratropium or honey) associated with usual care and the usual care in adults with acute bronchitis.Methods and analysisThis will be a multicentre, pragmatic, parallel group, open randomised trial. Patients aged 18 or over with uncomplicated acute

APA, Harvard, Vancouver, ISO, and other styles

36

Antus, Balazs. "Pharmacotherapy of Chronic Obstructive Pulmonary Disease: A Clinical Review." ISRN Pulmonology 2013 (March 13, 2013): 1–11. http://dx.doi.org/10.1155/2013/582807.

Full text

Abstract:

Chronic obstructive pulmonary disease (COPD) is one of the leading causes of mortality and morbidity worldwide. In addition to generating high healthcare costs, COPD imposes a significant burden in terms of disability and impaired quality of life. Unlike many leading causes of death and disability, COPD is projected to increase in many regions of the world as the frequency of smoking is rising and the population is aging. The pharmacological treatment of COPD includes bronchodilators to relax smooth muscle, such as β2-agonists (salbutamol, terbutaline, and fenoterol, short-acting β2-agonists a

APA, Harvard, Vancouver, ISO, and other styles

37

Gorzoni, Milton Luiz, and Renato Moraes Alves Fabbri. "Applicability of Anticholinergic Risk Scale in hospitalized elderly persons." Revista Brasileira de Geriatria e Gerontologia 20, no. 1 (2017): 123–28. http://dx.doi.org/10.1590/1981-22562017020.150191.

Full text

Abstract:

Abstract Objective: to define the applicability of the Anticholinergic Risk Scale (ARS) as a risk indicator of delirium in hospitalized elderly persons. Method: the medical records of elderly patients hospitalized in the medical wards of a teaching hospital were analyzed with the ARS, translated and adapted for medicines used in Brazil. The version of the Confusion Assessment Method (CAM) for the clinical diagnosis of delirium translated and validated by Fabbri et al. was used. Individuals aged ≥60 years were included in the evaluation of drug use. The sample was divided by gender and age to a

APA, Harvard, Vancouver, ISO, and other styles

38

Nakanishi, Takeo, Yoshitaka Hasegawa, Tsunemitsu Haruta, Tomohiko Wakayama, and Ikumi Tamai. "In Vivo Evidence of Organic Cation Transporter-Mediated Tracheal Accumulation of the Anticholinergic Agent Ipratropium in Mice." Journal of Pharmaceutical Sciences 102, no. 9 (2013): 3373–81. http://dx.doi.org/10.1002/jps.23603.

Full text

APA, Harvard, Vancouver, ISO, and other styles

39

Dasta, Joseph F., David A. Kuhl, Olakunbi A. Agiri, and Laurie S. Mauro. "Beta-Agonists in the Treatment of Acute Exacerbation of Chronic Obstructive Pulmonary Disease." Annals of Pharmacotherapy 28, no. 12 (1994): 1379–88. http://dx.doi.org/10.1177/106002809402801209.

Full text

Abstract:

OBJECTIVE: To critically evaluate the following issues regarding the use of beta-agonists in the treatment of acute exacerbations of chronic obstructive pulmonary disease (COPD): (1) optimal dose, (2) use of nebulizer (NEB) versus metered-dose inhaler-spacer devices (MDISs), (3) comparison with anticholinergic agents, and (4) use in mechanically ventilated patients. The patient populations addressed are limited primarily to emergency department (ED) and intensive care/acute care settings. DATA SOURCES: English-language journal articles published between 1977 and 1993. STUDY SELECTION: Nine stu

APA, Harvard, Vancouver, ISO, and other styles

40

Pavlova, K. S., D. S. Mdinaradze та O. M. Kurbacheva. "ВАРИАБЕЛЬНОСТЬ ОТВЕТА НА СТАНДАРТНУЮ ФАРМАКОТЕРАПИЮ У ПАЦИЕНТОВ С БРОНХИАЛЬНОЙ АСТМОЙ". Rossiiskii Allergologicheskii ZHurnal, № 2 part: 16 (11 липня 2019): 20–24. http://dx.doi.org/10.36691/raj.2019.2.42283.

Full text

Abstract:

Актуальность. Основанием для проведения данного исследования послужило наличие группы пациентов с бронхиальной астмой (БА), которые предпочитают для купирования приступов удушья использовать короткодействующие антихолинергические препараты (КДХП). Цель. Изучение возможной низкой эффективности длительно действующих Р2агонистов (ДДБА) у пациентов с БА, не имеющих достаточного ответа на КДБА, а также вероятности уменьшения бронхиальной обструкции с помощью длительно действующих антихолинергических препаратов (ДДХП) у этих пациентов. Материалы и методы. В исследовании приняли участие 12 взрослых н

APA, Harvard, Vancouver, ISO, and other styles

41

Beauchesne, Marie-France. "Management of Chronic Obstructive Pulmonary Disease: A Review." Journal of Pharmacy Practice 14, no. 2 (2001): 126–42. http://dx.doi.org/10.1106/777c-kd4j-ym5x-xw1m.

Full text

Abstract:

Chronic obstructive pulmonary disease (COPD) affects about 14 million persons in the United States and is the only common cause of death that is increasing in incidence. Chronic management of this disorder includes nonpharmacologic interventions such as smoking cessation, immunization, nutritional support, and pulmonary rehabilitation. The pharmacotherapy of COPD is based on regular administration of bronchodilators, when symptoms are persistent. Long-acting bronchodilators have been shown to improve quality of life in patients with COPD. Ipratropium remains the anticholinergic of choice, but

APA, Harvard, Vancouver, ISO, and other styles

42

Cramer, Joyce A., Carole Bradley-Kennedy, and Alissa Scalera. "Treatment Persistence and Compliance with Medications for Chronic Obstructive Pulmonary Disease." Canadian Respiratory Journal 14, no. 1 (2007): 25–29. http://dx.doi.org/10.1155/2007/161652.

Full text

Abstract:

BACKGROUND AND OBJECTIVE: Inhaled beta-agonist, anticholinergic and glucocorticoid medications are used to treat asthma and chronic obstructive pulmonary disease (COPD). The present study assessed the patterns of persistence with the above mentioned inhaled medications.METHODS: Prescription claims data from the Ontario Drug Benefit Program were analyzed to assess persistence (time to discontinuation) and compliance (percentage of days with doses available divided by days to last refill) of patients prescribed inhaled medications. Patients were grouped as naive (no inhaled medication in the pre

APA, Harvard, Vancouver, ISO, and other styles

43

Jaćović-Knežević, Nataša, and Dragana Atanasijević. "Medicaton shortages: The Serbian experience." Glasnik javnog zdravlja 98, no. 4 (2024): 245–54. https://doi.org/10.5937/serbjph2404245j.

Full text

Abstract:

Medication shortage represents a situation in which the supply of a medicinal product that is authorised and placed on the market in a Member State does not meet demand for that medicinal product at a national level, whatever the cause (EU Regulation 2022/123). In Europe, medication shortage shows a growing trend and has an enormous impact on patients. Medication shortage occurs at all levels of healthcare and includes both essential life-saving medication, as well as medication used in broad application in numerous population groups. Medication shortage can be caused by economic, manufacturin

APA, Harvard, Vancouver, ISO, and other styles

44

Michele, C., L. Vera–Mondazzi, D. Trunfio, et al. "ENOXIMONE AS A THERAPEUTIC OPTION IN STATUS ASTHMATICUS: A CASE REPORT." European Heart Journal Supplements 26, Supplement_2 (2024): ii78. http://dx.doi.org/10.1093/eurheartjsupp/suae036.183.

Full text

Abstract:

Abstract Status asthmaticus is an acute exacerbation of asthma that is unresponsive to initial treatment with bronchodilators and can rapidly escalate into acute ventilatory failure. The clinical picture of severe asthma include agitation, drowsiness or confusion, breathlessness at rest, tachypnea, use of accessory respiratory muscles, tachycardia, and pulsus paradoxus. Pharmacological treatments include but are not limited to beta–2–mimetics, anticholinergic agents, magnesium sulphate, steroids and aminophylline. Asthma exacerbations can be triggered by interrupting chronic treatment: in war

APA, Harvard, Vancouver, ISO, and other styles

45

Hong, Hai-yu, Zhen-peng Liao, Qin-tai Yang, et al. "Expert consensus on nasal anticholinergics in the treatment of allergic rhinitis." International Journal of Surgery: Global Health 8, no. 1 (2024). https://doi.org/10.1097/gh9.0000000000000480.

Full text

Abstract:

Background: Allergic rhinitis (AR) is a common hyperreactive nasal disease in otolaryngology, mainly manifested as rhinorrhea, nasal obstruction, nasal itching, and sneezing. Despite medication and immunotherapy, a large proportion of patients do not completely eliminate rhinorrhea. In recent years, the use of nasal anticholinergics in the treatment of AR has gained attention. However, there is currently no consensus on the timing and selection of nasal anticholinergics for AR treatment. Summary: We reviewed previous studies on nasal anticholinergic drugs in AR and summarized the pathogenesis

APA, Harvard, Vancouver, ISO, and other styles

46

Askoura, Anas Mohamed, Sabry Magdy Sabry, Samia Ahmed Fawaz, Manal Ibrahim Salman, Moustafa Ahmed Mahmoud Anter El sordy, and Ossama Mustafa Mady. "Effect of topical anticholinergic medication on clinical manifestations control among patients with vasomotor rhinitis versus allergic rhinitis: as comparative clinical trials." Egyptian Journal of Otolaryngology 39, no. 1 (2023). http://dx.doi.org/10.1186/s43163-023-00414-2.

Full text

Abstract:

Abstract Background The use of a topical anticholinergic medication, ipratropium bromide, and its ability to inhibit methacholine and rhinitis-induced hypersecretion is emphasized. Ipratropium bromide appears to be both safe and effective in reducing this troublesome symptom. This study is designed to show the therapeutic effect of anticholinergic local treatment on nasal mucosa in patients with vasomotor rhinitis. Objective To assess the therapeutic effect of local anticholinergic treatment on nasal mucosa in patients with vasomotor rhinitis compared to non-vasomotor (allergic) patients and n

APA, Harvard, Vancouver, ISO, and other styles

47

Wong, Bryant, Sriya Sai Pushpa Datla, Cindy Li, Christine Joyce, and Joseph Alzagatiti. "Developing anticholinergic drugs for the treatment of asthma with improved efficacy." Journal of Emerging Investigators, 2023. http://dx.doi.org/10.59720/22-173.

Full text

Abstract:

Anticholinergics are used in treating asthma, a chronic inflammation of the airways. These drugs block human M1 and M2 muscarinic acetylcholine receptors, inhibiting bronchoconstriction. However, studies have reported complications of anticholinergic usage, such as exacerbated eosinophil production and worsened urinary retention. Modification of known anticholinergics using bioisosteric replacements to increase efficacy could potentially minimize these complications. The present study focuses on identifying viable analogs of anticholinergics to improve binding energy to the receptors compared

APA, Harvard, Vancouver, ISO, and other styles

48

"Sustained-release theophylline preparations." Drug and Therapeutics Bulletin 23, no. 9 (1985): 33–36. http://dx.doi.org/10.1136/dtb.23.9.33.

Full text

Abstract:

Oral theophyllines have long been used to treat airway narrowing in patients with asthma and chronic bronchitis.1 Their popularity waned when effective local treatment became available with inhaled β2 stimulants, and later with the anticholinergic drug ipratropium bromide. They are now being used more widely again since the advent of sustained-release (s/r) preparations, several of them strongly promoted. When are they worth using?

APA, Harvard, Vancouver, ISO, and other styles

49

Sabry, Sabry Magdy, Samia Ahmed Fawaz, Manal Ibrahim Salman, Anas Mohamed Askoura, Ossama Mustafa Mady, and Moustafa Ahmed Mahmoud Anter El sordy. "Efficacy of Topical Anticholinergic in Control of Symptoms in Patients with Vasomotor Rhinitis and non-Vasomotor Rhinitis Patients and Normal Individuals. A Controlled Comparative Study." QJM: An International Journal of Medicine 117, Supplement_1 (2024). http://dx.doi.org/10.1093/qjmed/hcae070.191.

Full text

Abstract:

Abstract Background The use of a topical anticholinergic medication, ipratropium bromide, and its ability to inhibit methacholine and rhinitis-induced hypersecretion is emphasized. Ipratropium bromide appears to be both safe and effective in reducing this troublesome symptom. This study is designed to show the therapeutic effect of anticholinergic local treatment on nasal mucosa in patients with vasomotor rhinitis. Objective To assess the therapeutic effect of local anticholinergic treatment on nasal mucosa in patients with vasomotor rhinitis compared to non-vasomotor (allergic) patients and n

APA, Harvard, Vancouver, ISO, and other styles

50

Novelli, F., F. Costa, M. Latorre, et al. "Tiotropium: a new therapeutic option in asthma." Monaldi Archives for Chest Disease 79, no. 3-4 (2013). http://dx.doi.org/10.4081/monaldi.2013.5208.

Full text

Abstract:

Tiotropium: a new therapeutic option in asthma. F. Novelli, F. Costa, M. Latorre, L. Malagrinò, A. Celi, B. Vagaggini, P. Paggiaro. Although bronchial hyperresponsiveness to cholinergic agents is a main feature of asthma, the role of anticholinergic drugs in chronic asthma management has been largely underestimated. Several single-dose studies comparing acute bronchodilation induced by ipratropium bromide with salbutamol have shown that salbutamol is more effective than ipratropium in treating asthma. Recently, tiotropium has been studied in asthma, when added to low-medium dose inhaled cortic

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!